RGNX
Regenxbio Inc
NASDAQ: RGNX · HEALTHCARE · BIOTECHNOLOGY
$9.62
+0.21% today
Updated 2026-07-29
Market cap
$579.01M
P/E ratio
—
P/S ratio
6.59x
EPS (TTM)
$-5.60
Dividend yield
—
52W range
$5 – $16
Volume
2.3M
Regenxbio Inc (RGNX) Insider transactions
Net insider activity
Net buying (3,305,068 shares)
Buy transactions
66
Sell transactions
34
All transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-02 | PAKOLA, STEVE | Chief Medical Officer | Sale | 2,161 | — | — |
| 2026-07-02 | PAKOLA, STEVE | Chief Medical Officer | Buy | 2,161 | $7.86 | $16985.46 |
| 2026-07-01 | SIMPSON, CURRAN | Director, Chief Executive Officer | Sale | 6,818 | $13.09 | $89247.62 |
| 2026-07-01 | PAKOLA, STEVE | Chief Medical Officer | Sale | 36,725 | — | — |
| 2026-07-01 | PAKOLA, STEVE | Chief Medical Officer | Buy | 36,725 | $7.86 | $288658.50 |
| 2026-06-30 | SIMPSON, CURRAN | Director, Chief Executive Officer | Buy | 1,453 | $10.18 | $14791.54 |
| 2026-06-29 | PAKOLA, STEVE | Chief Medical Officer | Sale | 19,608 | $11.04 | $216472.32 |
| 2026-05-29 | ZACHARY, JENNIFER | Director | Buy | 46,600 | — | — |
| 2026-05-29 | ZACHARY, JENNIFER | Director | Buy | 9,807 | — | — |
| 2026-05-29 | TASSE, DANIEL | Director | Buy | 46,600 | — | — |
| 2026-05-29 | TASSE, DANIEL | Director | Buy | 9,807 | — | — |
| 2026-05-29 | STUMP, DAVID C | Director | Buy | 46,600 | — | — |
| 2026-05-29 | STUMP, DAVID C | Director | Buy | 9,807 | — | — |
| 2026-05-29 | MILLS, KENNETH T. | Director | Buy | 46,600 | — | — |
| 2026-05-29 | MILLS, KENNETH T. | Director | Buy | 9,807 | — | — |
| 2026-05-29 | MIGAUSKY, GEORGE V | Director | Buy | 46,600 | — | — |
| 2026-05-29 | MIGAUSKY, GEORGE V | Director | Buy | 9,807 | — | — |
| 2026-05-29 | KARABELAS, ARGERIS N | Director | Buy | 46,600 | — | — |
| 2026-05-29 | KARABELAS, ARGERIS N | Director | Buy | 9,807 | — | — |
| 2026-05-29 | GLUCKSMANN, ALEXANDRA | Director | Buy | 46,600 | — | — |
| 2026-05-29 | GLUCKSMANN, ALEXANDRA | Director | Buy | 9,807 | — | — |
| 2026-05-29 | FOX, ALLAN M. | Director | Buy | 46,600 | — | — |
| 2026-05-29 | FOX, ALLAN M. | Director | Buy | 9,807 | — | — |
| 2026-05-29 | BENNETT, JEAN | Director | Buy | 46,600 | — | — |
| 2026-05-29 | BENNETT, JEAN | Director | Buy | 9,807 | — | — |
| 2026-05-11 | PAKOLA, STEVE | Chief Medical Officer | Sale | 15,309 | $11.02 | $168705.18 |
| 2026-03-10 | PAKOLA, STEVE | Chief Medical Officer | Sale | 5,124 | $10.35 | $53033.40 |
| 2026-02-01 | PAKOLA, STEVE | Chief Medical Officer | Sale | 5,267 | $11.16 | $58779.72 |
| 2026-02-01 | CHRISTMAS, PATRICK J. | Chief Strategy & Legal Officer | Sale | 4,700 | $11.16 | $52452.00 |
| 2026-01-27 | MILLS, KENNETH T. | Director | Sale | 225,000 | — | — |
| 2026-01-27 | MILLS, KENNETH T. | Director | Buy | 225,000 | $13.09 | $2.95M |
| 2026-01-27 | MILLS, KENNETH T. | Director | Sale | 221,753 | $13.41 | $2.97M |
| 2026-01-06 | SIMPSON, CURRAN | Director, Chief Executive Officer | Buy | 233,651 | — | — |
| 2026-01-06 | SIMPSON, CURRAN | Director, Chief Executive Officer | Buy | 144,864 | — | — |
| 2026-01-06 | PAKOLA, STEVE | Chief Medical Officer | Buy | 35,402 | — | — |
| 2026-01-06 | PAKOLA, STEVE | Chief Medical Officer | Buy | 65,847 | — | — |
| 2026-01-06 | MALZAHN, CRAIG | Chief Technology Officer | Buy | 35,402 | — | — |
| 2026-01-06 | MALZAHN, CRAIG | Chief Technology Officer | Buy | 65,847 | — | — |
| 2026-01-06 | CHRISTMAS, PATRICK J. | Chief Strategy & Legal Officer | Buy | 39,650 | — | — |
| 2026-01-06 | CHRISTMAS, PATRICK J. | Chief Strategy & Legal Officer | Buy | 73,749 | — | — |
| 2026-01-06 | CHAN, MITCHELL | Chief Financial Officer | Buy | 39,650 | — | — |
| 2026-01-06 | CHAN, MITCHELL | Chief Financial Officer | Buy | 73,749 | — | — |
| 2026-01-02 | SIMPSON, CURRAN | Director, Chief Executive Officer | Sale | 18,559 | $14.40 | $267249.60 |
| 2026-01-02 | PAKOLA, STEVE | Chief Medical Officer | Sale | 18,247 | $14.40 | $262756.80 |
| 2026-01-02 | MALZAHN, CRAIG | Chief Technology Officer | Sale | 1,238 | $14.40 | $17827.20 |
| 2026-01-02 | CHRISTMAS, PATRICK J. | Chief Strategy & Legal Officer | Sale | 9,793 | $14.40 | $141019.20 |
| 2025-12-31 | SIMPSON, CURRAN | Director, Chief Executive Officer | Buy | 951 | $7.00 | $6652.72 |
| 2025-10-09 | SIMPSON, CURRAN | Director, Chief Executive Officer | Sale | 20,811 | $12.62 | $262634.82 |
| 2025-09-29 | SIMPSON, CURRAN | Director, Chief Executive Officer | Sale | 7,624 | $10.03 | $76468.72 |
| 2025-09-10 | SIMPSON, CURRAN | Director, Chief Executive Officer | Sale | 7,734 | $10.02 | $77494.68 |
| 2025-09-01 | MALZAHN, CRAIG | Chief Technology Officer | Sale | 234 | $8.93 | $2089.62 |
| 2025-09-01 | CHAN, MITCHELL | Chief Financial Officer | Sale | 4,901 | $8.93 | $43765.93 |
| 2025-08-01 | CHRISTMAS, PATRICK J. | Chief Strategy & Legal Officer | Sale | 4,699 | $8.19 | $38484.81 |
| 2025-07-01 | SIMPSON, CURRAN | Director, Chief Executive Officer | Sale | 4,701 | $8.23 | $38689.23 |
| 2025-05-30 | ZACHARY, JENNIFER | Director | Buy | 39,815 | — | — |
| 2025-05-30 | ZACHARY, JENNIFER | Director | Buy | 7,768 | — | — |
| 2025-05-30 | TASSE, DANIEL | Director | Buy | 39,815 | — | — |
| 2025-05-30 | TASSE, DANIEL | Director | Buy | 7,768 | — | — |
| 2025-05-30 | STUMP, DAVID C | Director | Buy | 39,815 | — | — |
| 2025-05-30 | STUMP, DAVID C | Director | Buy | 7,768 | — | — |
| 2025-05-30 | MILLS, KENNETH T. | Director | Buy | 39,815 | — | — |
| 2025-05-30 | MILLS, KENNETH T. | Director | Buy | 7,768 | — | — |
| 2025-05-30 | MIGAUSKY, GEORGE V | Director | Buy | 39,815 | — | — |
| 2025-05-30 | MIGAUSKY, GEORGE V | Director | Buy | 7,768 | — | — |
| 2025-05-30 | KARABELAS, ARGERIS N | Director | Buy | 39,815 | — | — |
| 2025-05-30 | KARABELAS, ARGERIS N | Director | Buy | 7,768 | — | — |
| 2025-05-30 | GLUCKSMANN, ALEXANDRA | Director | Buy | 39,815 | — | — |
| 2025-05-30 | GLUCKSMANN, ALEXANDRA | Director | Buy | 7,768 | — | — |
| 2025-05-30 | FOX, ALLAN M. | Director | Buy | 39,815 | — | — |
| 2025-05-30 | FOX, ALLAN M. | Director | Buy | 7,768 | — | — |
| 2025-05-30 | BENNETT, JEAN | Director | Buy | 39,815 | — | — |
| 2025-05-30 | BENNETT, JEAN | Director | Buy | 7,768 | — | — |
| 2025-05-12 | MILLS, KENNETH T. | Director | Sale | 20,602 | — | — |
| 2025-05-12 | MILLS, KENNETH T. | Director | Buy | 20,602 | $3.76 | $77463.52 |
| 2025-03-27 | MILLS, KENNETH T. | Director | Sale | 30,752 | — | — |
| 2025-03-27 | MILLS, KENNETH T. | Director | Buy | 30,752 | $3.76 | $115627.52 |
| 2025-02-01 | PAKOLA, STEVE | Chief Medical Officer | Sale | 5,263 | $8.07 | $42472.41 |
| 2025-02-01 | DANOS, OLIVIER | Chief Scientific Officer | Sale | 5,452 | $8.07 | $43997.64 |
| 2025-02-01 | CHRISTMAS, PATRICK J. | Chief Legal Officer | Sale | 4,700 | $8.07 | $37929.00 |
| 2025-01-02 | SIMPSON, CURRAN | Director, Chief Executive Officer | Buy | 478,606 | — | — |
| 2025-01-02 | SIMPSON, CURRAN | Director, Chief Executive Officer | Buy | 476,606 | — | — |
| 2025-01-02 | SIMPSON, CURRAN | Director, Chief Executive Officer | Buy | 98,912 | — | — |
| 2025-01-02 | SIMPSON, CURRAN | Director, Chief Executive Officer | Sale | 11,917 | $7.73 | $92118.41 |
| 2025-01-02 | PAKOLA, STEVE | Chief Medical Officer | Buy | 103,698 | — | — |
| 2025-01-02 | PAKOLA, STEVE | Chief Medical Officer | Buy | 64,293 | — | — |
| 2025-01-02 | PAKOLA, STEVE | Chief Medical Officer | Sale | 13,891 | $7.73 | $107377.43 |
| 2025-01-02 | DANOS, OLIVIER | Chief Scientific Officer | Buy | 95,721 | — | — |
| 2025-01-02 | DANOS, OLIVIER | Chief Scientific Officer | Buy | 59,347 | — | — |
| 2025-01-02 | DANOS, OLIVIER | Chief Scientific Officer | Sale | 12,630 | $7.73 | $97629.90 |
| 2025-01-02 | CHRISTMAS, PATRICK J. | Chief Legal Officer | Buy | 223,350 | — | — |
| 2025-01-02 | CHRISTMAS, PATRICK J. | Chief Legal Officer | Sale | 11,395 | $7.73 | $88083.35 |
| 2025-01-02 | CHAN, MITCHELL | Chief Financial Officer | Buy | 62,547 | — | — |
| 2024-10-01 | KARABELAS, ARGERIS N | Director | Sale | 10,000 | — | — |
| 2024-10-01 | KARABELAS, ARGERIS N | Director | Buy | 10,000 | $3.76 | $37600.00 |
| 2024-09-16 | CHAN, MITCHELL | Chief Financial Officer | Buy | 289,362 | — | — |
| 2024-09-16 | CHAN, MITCHELL | Chief Financial Officer | Buy | 58,869 | — | — |
| 2024-09-03 | KARABELAS, ARGERIS N | Director | Sale | 10,000 | — | — |
| 2024-09-03 | KARABELAS, ARGERIS N | Director | Buy | 10,000 | $3.76 | $37600.00 |
| 2024-09-03 | KARABELAS, ARGERIS N | Director | Sale | 9,300 | $11.50 | $106950.00 |
| 2024-09-03 | KARABELAS, ARGERIS N | Director | Sale | 700 | $12.34 | $8638.00 |
Frequently asked questions
Are RGNX insiders buying or selling?
Over the transactions on record, RGNX insiders have been net buyers, with about $5.47M in stock sold across 34 sales, against 9 open-market purchases.
Does insider selling at RGNX mean the stock will fall?
Not by itself. Most executive selling is pre-scheduled through 10b5-1 plans filed months in advance, and insiders sell for diversification, taxes, and liquidity far more often than out of any view on the price. Insider buying is the stronger signal, especially when several insiders buy around the same time, because there is usually only one reason to put personal cash into the stock.
Which RGNX insiders are selling the most?
Recent selling is concentrated in a few names. MILLS, KENNETH T. accounts for the largest share on record, with about $2.97M sold. Selling by one or two individuals matters less than broad selling across the whole leadership team, which is the pattern worth watching.